A Study of Baricitinib (LY3009104) in Adult and Pediatric Japanese Participants With NNS/CANDLE, SAVI, and AGS

Aicardi Goutieres Syndrome Clinical Trial

Official title:
A Phase 2/3, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Baricitinib in Adult and Pediatric Japanese Patients With NNS/CANDLE, SAVI, and AGS

Status Active, not recruiting

Clinical Trial Summary

The main purpose of this study is to evaluate the efficacy and safety of baricitinib in adult and pediatric Japanese participants with Nakajo-Nishimura Syndrome/chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature (NNS/CANDLE), STING-associated vasculopathy with onset during infancy (SAVI), and Aicardi-Goutières Syndrome (AGS).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Aicardi Goutieres Syndrome
Chronic Atypical Neutrophilic Dermatosis With Lipodystrophy and Elevated Temperature Syndrome
Fever
Hyperthermia
Lipodystrophy
Nakajo-Nishimura Syndrome
Skin Diseases
STING-Associated Vasculopathy With Onset in Infancy
Syndrome

Clinical Trial Details

NCT number	NCT04517253
Study type	Interventional
Source	Eli Lilly and Company
Contact
Status	Active, not recruiting
Phase	Phase 2/Phase 3
Start date	October 27, 2020
Completion date	April 30, 2025

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03921554` - JAK Inhibitor Treatment in AGS	Phase 2
Active, not recruiting	`NCT02699190` - LeukoSEQ: Whole Genome Sequencing as a First-Line Diagnostic Tool for Leukodystrophies
Recruiting	`NCT03047369` - The Myelin Disorders Biorepository Project